

**2014 Pharmaceutical Price Regulation Scheme (PPRS)
Aggregate Net Sales and Payment Information**

26 February 2015

The table below sets out aggregate information on:

- Net sales for quarters 1-4 of calendar year 2013;
- Net sales and payments for quarters 1-4 of calendar year 2014.

There are two columns for net sales information:

- Net sales subject to branded medicines bill growth calculation (Measured Spend)¹;
- Net sales covered by the PPRS Payment².

The table sets out information held on the Department of Health PPRS Operations database on 26 February 2015. The aggregate payments total is the total of payments actually received by the Department at that date.

In the table below, for companies that have exited the 2014 PPRS, their reported sales have been excluded from the Aggregate Net Sales Subject to Medicines Bill Growth Calculation (Measured Spend). However, the table does include such companies' reported sales within Aggregate Net Sales Covered by PPRS Payment and Aggregate Payments Received by the Department of Health for the period that they were members of the 2014 PPRS. This is also currently the position for companies that joined the PPRS in the last quarter of 2014.

Please note that the data is subject to correction of errors and has not yet been audited. The audit and reconciliation arrangements are set out in paragraphs 6.24-6.30 and 6.37-6.40 of the PPRS.

Our intention is:

- At each quarterly publication point, to publish an update of all the previous quarters' figures until the point at which audited data is published for the year concerned.
- Following the receipt of complete audited information, to publish annual audited data. Once annual audited data has been published there would be no further updates of those quarters³.
- To publish any revisions to data following the 2016 reconciliation exercise.

	Aggregate Net Sales Subject to Medicines Bill Growth Calculation (Measured Spend)	Aggregate Net Sales Covered by the PPRS Payment	Aggregate Payments Received by the Department of Health
2013 Q1	£1,846M	£1,861M	N/A
2013 Q2	£1,924M	£1,940M	N/A
2013 Q3	£1,983M	£1,997M	N/A
2013 Q4	£2,117M	£2,133M	N/A
2014 Q1	£1,969M	£1,981M	£74M
2014 Q2	£2,018M	£2,024M	£76M
2014 Q3	£2,106M	£2,101M	£79M
2014 Q4	£2,186M	£2,168M	£76M ⁴

¹Measured spend is defined in paragraph 6.6 of the PPRS and means the spend which is controlled by the PPRS Payments mechanism. It includes sales of new products.

²Sales covered by the PPRS Payment is defined at paragraph 6.7 of the PPRS. The percentage payment applies to these sales, which exclude sales of new products. Sales of new products are included in the calculation of the overall sum to be repaid across all member companies. However, products with a new active substance designation that are introduced after 31 December 2013 are excluded from the sales used to calculate the payment by each company.

³Companies are required to provide audited annual data nine months after the end of their financial year. For 2013 final audited data would be published once the audited returns for companies with financial years ending in 2013 have been received and collated.

⁴Aggregate PPRS Payments due from scheme members in 2014 Q4 is £81 million. £5 million remains to be received at current date.